IRVINE, Calif., May 9, 2019 /PRNewswire/ -- Cryoport, Inc.
(NASDAQ: CYRX) (NASDAQ: CYRXW) ("Company"), the world's leading
temperature-controlled logistics company dedicated to the life
sciences industry, announced today its 2nd annual
workshop, titled, 'Process Considerations for Cryogenic and
Regenerative Medicine Commercialization,' taking place on
Wednesday, May 15, 2019 at the
Business Design Centre in London, United
Kingdom. The educational workshop is taking place in
conjunction with the World Advanced Therapies &
Regenerative Medicine Congress event and is aimed at
biotechnology and pharmaceutical professionals who want to learn
more about the critical considerations for the development and
commercialization of vital regenerative medicine therapies.
The workshop will feature topics on:
- Integration and Data Continuity Throughout the Regenerative
Medicine Production Process
- Systems Compliance and Traceability During Product
Distribution
- Regenerative Medicine Globalization: Considerations for
Effective Launch activity Beyond your Initial Geographic
Launch
- Scalability (Systems, Data, Infrastructure)
The workshop will include speakers from groundbreaking companies
in the regenerative medicine market, including Cryoport, GE
Healthcare, Be The Match BioTherapies, Mesoblast, Eversana, Hitachi
Chemical Advanced Therapeutic Solutions, Progenitor Therapeutics
and Royal Free London NHS Foundation Trust.
Mark Sawicki, Chief Commercial
Officer at Cryoport, commented, "The emergence of regenerative
medicine is shaping up to be one of the greatest achievements of
modern medicine. However, regenerative medicine commodities are
inherently fragile and more at risk than other products during the
supply chain process. Cross-contamination, orientation and handling
problems, and equipment failure all have the potential to damage
these irreplaceable materials. This workshop brings together
dedicated individuals and companies that are at the forefront of
the regenerative medicine industry and who are committed to
overcoming these challenges in order to bring life changing
therapies to patients. With new regulations anticipated to affect
all aspects of the collection, manufacture, transportation, and
administration of regenerative medicines, it is now more important
than ever for biopharmaceutical companies to be aware of best
practices when advancing their therapies through the clinical trial
pipeline and into commercialization. This workshop will prove to be
a great platform for learning and collaboration for those involved
in regenerative medicine."
For more information about this event please visit
www.cryoport.com/workshop, call +1 949 681 2772, or
email workshop@cryoport.com.
About the World Advanced Therapies & Regenerative
Medicine Congress
The World Advanced Therapies &
Regenerative Medicine Congress is an exhibition and conference that
has grown to become one of the best and most established cell and
gene events in the world today. The 2019 edition will be in its
14th year and it continues to grow and attract a large audience of
biotech, pharma, start-ups, investors, research and technology
companies from around the world. The conference and exhibition will
host over 1,000 attendees, 300 speakers and 80 exhibition booths.
Over 500 different global companies are represented every year at
this event.
About Cryoport, Inc.
Cryoport is the life sciences
industry's most trusted global provider of temperature-controlled
logistics solutions for temperature-sensitive life sciences
commodities, serving the biopharmaceutical market with leading-edge
logistics solutions for biologic materials, such as regenerative
medicine, including immunotherapies, stem cells and CAR T-cells.
Cryoport's solutions are used by points-of-care, CRO's, central
laboratories, pharmaceutical companies, manufacturers, university
researchers et al; as well as the reproductive medicine market,
primarily in IVF and surrogacy; and the animal health market,
primarily in the areas of vaccines and reproduction. Cryoport's
proprietary Cryoport Express® Shippers, Cryoportal® Logistics
Management Platform, leading-edge SmartPak II™ Condition Monitoring
System and geo-sensing technology, paired with unparalleled cold
chain logistics expertise and 24/7 client support, make Cryoport
the end-to-end cold chain logistics partner that the industry
trusts.
Cryoport is dedicated to: simplifying global cold chain
logistics through innovative technology, unmatched monitoring and
data capture and support, including consulting; delivering the most
advanced temperature-controlled logistics solutions for the life
sciences industry; and providing vital information that provides
peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to
follow @cryoport on
Twitter at www.twitter.com/cryoport.
Forward Looking Statements
Statements in
this news release which are not purely historical, including
statements regarding Cryoport, Inc.'s intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results could differ materially
from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are
not limited to, risks and uncertainties associated with the effect
of changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
listed from time to time in the Company's SEC reports including,
but not limited to, the Company's 10-K for the year ended
December 31, 2018 filed with the SEC.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release.
Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cryoport-to-host-workshop-at-14th-annual-world-advanced-therapies--regenerative-medicine-congress-on-wednesday-may-15th-300847092.html
SOURCE Cryoport, Inc.